Drug Profile
Research programme: inflammatory skin diseases therapeutics - Johnson & Johnson/Crown Laboratories
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Xycrobe Therapeutics
- Developer Crown Laboratories; Johnson & Johnson Innovation
- Class Skin disorder therapies
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne; Dermatitis; Eczema; Psoriasis; Skin disorders
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Acne in USA (Topical)
- 28 Sep 2020 No recent reports of development identified for research development in Dermatitis in USA (Topical)
- 28 Sep 2020 No recent reports of development identified for research development in Eczema in USA (Topical)